AstraZeneca secured a Federal Court injunction in Australia blocking Pharmacor from selling generic dapagliflozin while a ...

AstraZeneca's full-year 2025 results are due on 10 February. Learn what investors should watch including Tagrisso sales, ...

Fallopian tube cancer, a rare gynecologic cancer, is gaining awareness due to its potential origin for many high-grade serous ovarian cancers. New diagnostics improve early detection and treatment, ...

AstraZeneca PLC (NASDAQ:AZN) is one of the stocks in focus on Jim Cramer’s game plan. Cramer mentioned the company during the ...

Amgen and AstraZeneca have reported complete outcomes from the registrational Phase III WAYPOINT trial of Tezspire (tezepelumab-ekko) for treating chronic rhinosinusitis with nasal polyps (CRSwNP).

AZN gears up for Q4 results as cancer, diabetes and rare disease drugs drive sales expectations ahead of the Feb. 10 earnings report.

The company's shares rose 11% in the fourth quarter to close at 137.90 pounds on Dec. 31.

AstraZeneca CEO Pascal Soriot on Tuesday reiterated the pharmaceutical firm's commitment to the U.S. market amid reports that he is considering shifting its listing stateside. Stream Los Angeles News ...

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner at Cerity Partners, named AstraZeneca PLC (NASDAQ:AZN) as his final trade. On Aug. 20, AstraZeneca released complete results from the ...

AstraZeneca (NASDAQ:AZN) ADRs added ~2% in the morning hours on Tuesday after The Times reported that CEO Sir Pascal Soriot has privately indicated his willingness to shift the company’s stock listing ...

Chinese prosecutors have brought formal charges against AstraZeneca and its former executives following investigations into alleged illegal patient data collection and importation of drugs. | Chinese ...